Can-Fite BioPharma Ltd. reported H1 2026 financial results showing a net loss of $4.6 million, compared to $4.87 million in the prior year period. Revenues remained flat at $0.2 million, while R&D expenses increased by 13.9% to $3.45 million and G&A expenses decreased by 31.4% to $1.42 million. The company raised approximately $4.0 million in gross proceeds from the exercise of existing warrants under an inducement agreement executed on March 4, 2026. Clinically, the pivotal Phase III study for Namodenoson in hepatocellular carcinoma showed longer-than-anticipated overall survival, prompting an evaluation for earlier interim analysis. The company also completed enrollment in its Phase III psoriasis trial for Piclidenoson and announced a definitive agreement on September 2, 2026, to immediately exercise outstanding warrants at a reduced price of $2.50 per ADS. Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting oncological and inflammatory diseases.

On September 2, 2026, Can-Fite Biopharma Ltd. entered into an inducement offer letter with a warrant holder to exercise existing warrants for up to 1,591,738 American Depositary Shares at a reduced price of $2.50 per ADS, generating approximately $4.0 million in gross proceeds. In consideration, the Company issued new warrants to purchase up to 3,183,476 ADSs at an exercise price of $2.50 per ADS. The transaction closed on September 3, 2026, with H.C. Wainwright & Co., LLC acting as placement agent for fees totaling approximately 8% plus expenses. Can-Fite Biopharma Ltd. operates in the biotechnology industry, developing therapies for inflammatory and fibrotic diseases.

Can-Fite BioPharma Ltd. announced the exercise of outstanding warrants for approximately $4.0 million in gross proceeds on September 2, 2026. The company issued 1,591,738 American Depositary Shares (ADSs) at a reduced exercise price of $2.50 per ADS, down from the original $5.00 strike price. In exchange for this cash injection, Can-Fite issued new unregistered warrants to purchase up to 3,183,476 additional ADSs, also exercisable at $2.50 per share until September 2028. H.C. Wainwright & Co. served as the exclusive placement agent for the transaction. The net proceeds are intended to fund research and development, clinical trials, and general corporate purposes. Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company developing proprietary small molecule drugs targeting oncological and inflammatory diseases.

Can-Fite BioPharma Ltd. announced on September 2, 2026, that blinded overall survival data from its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma appears longer than originally anticipated based on initial study design assumptions. The company is evaluating an earlier timing for the planned interim analysis to enable an independent assessment of overall survival between treatment groups. These observations reflect the pooled, blinded population including placebo recipients, so no conclusions regarding treatment efficacy can be drawn at this stage. Can-Fite BioPharma Ltd. operates in the biotechnology industry, developing proprietary small molecule drugs targeting oncological and inflammatory diseases.